For more information or to sign up for a trial
please contact our Clinical Trials Team:
(909) 478-7973
Trials by Tumor Types:
Breast Cancer Trials:
Breast - NCT05501886
VIKTORIA - 1 Breast Cancer Study | Now enrolling patients with ER+/HER2- advanced breast cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Open to enrollment
Colon Cancer Trials:
Colon – NCT05546476
Protocol C3651003
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period (PROACC-1)
Closed to enrollment
Lung Cancer Trials:
Lung - NCT05353257
Henlius 302 | Now enrolling adults that have been diagnosed with limited-stage small cell lung cancer (LS-SCLC)
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Closed to enrollment
Lung - NCT05785767
Protocol R3767-ONC-2235
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Open to entrollment
Lung - NCT05800015
Protocol R3767-ONC-2236
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
open to enrollment
Lung - NCT05671510
Protocol PRESERVE-003
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Open to Enrollment
Lung - NCT05546476
Protocol C3651003
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period (PROACC-1)
closed to enrollment
Prostate Cancer Trials:
Prostate - NCT06136650
Protocol MK5684-004
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
open to enrollment
Malignant Melanoma Trials:
No Active Trials
back to top ↑
Multiple Myeloma Trials:
Multiple Myeloma - NCT02952508
Protocol DCL-16-001
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)
Closed TO ENROLLMENT
Non-Hodgkin Lymphoma Trials:
Non-Hodgkin Lymphoma - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
Hematologic Malignancies Trials:
Hematologic - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
Hematologic - NCT05490446
Protocol AG946-C-002
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Open to enrollment
Hematologic - NCT06093672
Protocol DSC 08-2357-32
Phase 3 Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of Givinostat versus Hydroxyurea in JAK2V617F-positive high-risk Polycythemia Vera (GIV-IN PV) patients
open to enrollment
Hematologic - NCT02952508
Protocol DCL-16-001
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)
Closed TO ENROLLMENT
Other Trials:
Other - NCT05366881
cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
active - Closed to enrollment
Other - NCT02952508
Protocol DCL-16-001
An Open-Label, Multicenter, Phase 2 study of CLR 131 in patients with Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinema (CLOVER-WaM)
Closed TO ENROLLMENT
Other - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
Other - NCT05546476
Protocol C3651003
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period (PROACC-1)
